Orchid Cellmark's Q3 Revenue Stalls, Reliagene Deal Closes | GenomeWeb
NEW YORK (GenomeWeb News) — Orchid Cellmark yesterday closed its acquisition of DNA testing services provider Reliagene Technologies and today reported that its third-quarter revenue had inched back one percent, R&D spending fell 16 percent, and its net loss fell 46 percent.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.